Contact Us | Site Index | Legal
Research

Manuscripts

Selected publications by Company researchers or collaborators.

PubMed LogoPlease note that the links below go to the PubMed web site. PubMed is a service of the National Library of Medicine that includes over 16 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950's. PubMed includes links to full text articles and other related resources. These links will open in a new browser window. Please read NCBI's disclaimer and copyright notice.
CCR5 · HIV Entry Inhibitors · HIV Vaccine · Pro 140 · Methylnaltrexone · HCV · PSMA

CCR5

Cormier EG, Tran DNH, Yukhayeva L, Olson WC, Dragic T. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1gp120-CD4 complexes. Journal of Virology. 2001 Jun;75(12):5541-49.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11356961&query_hl=12&itool=pubmed_DocSum

Cormier EG, Persuh M, Thompson DA, Lin SW, Sakmar TP, Olson WC, Dragic T. Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proceedings of the National Academy of Sciences of the United States of America. 2000 May 23;97(11):5762-7.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10823934&query_hl=50&itool=pubmed_docsum
Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Chang-Mayer C, Robinson J, Maddon PJ, Moore JP. CD-4 dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 1996 Nov 14;384:184-87.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8906796&query_hl=16&itool=pubmed_DocSum

Litwin V, Nagashima KA, Ryder AM, Chang CH, Carver JM, Olson WC, Alizon M, Hasel KW, Maddon PJ, Allaway GP. Human Immumodeficiency Virus Type 1 Membrane Fusion Mediated by a Laboratory-Adapted Strain and a Primary Isolate Analyzed by Resonance Energy Transfer. Journal of Virology. 1996 Sept;70(9):6437-41.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8709277&query_hl=14&itool=pubmed_DocSum
Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996 Jun 20;381(6584):667-73.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8649512&query_hl=7&itool=pubmed_docsum


HIV ENTRY INHIBITORS

Huber M, Olson WC, Trkola A.
Antibodies for HIV treatment and prevention: window of opportunity?
Curr Top Microbiol Immunol. 2008;317:39-66. Review.
PMID: 17990789 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/pubmed/17990789?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Olson WC, Maddon PJ.
Resistance to HIV-1 Entry Inhibitors.
Current Drug Targets - Infectious Disorders. 2003 Dec;3(4):283-94. Review.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14754430&query_hl=31&itool=pubmed_DocSum
O'Hara BM, Olson WC.
HIV entry inhibitors in clinical development.
Current Opinion in Pharmacology. 2002 Oct;2(5):523-8. Review.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12324253&query_hl=56&itool=pubmed_docsum


HIV VACCINE

Beddows S, Schulke N, Kirschner M, Barnes K, Franti M, Michael E, Ketas T, Sanders RW, Maddon PJ, Olson WC, Moore JP.
Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
Journal of Virology. 2005 Jul;79(14):8812-27.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15994775&query_hl=9&itool=pubmed_docsum

Binley JM, Cayanan CS, Wiley C, Schülke N, Olson WC, Burton DR. Redox-Triggered Infection by Disulfide-Shackled HIV-1 Pseudovirions. Journal of Virology. 2003 May;77(10):5678-84.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12719560&query_hl=18&itool=pubmed_DocSum
Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman R, Paluch M, Berkhout B, Maddon PJ, Olson WC, Lu M, Moore JP. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. Journal of Virology. 2002 Sep;76(17):8875-89.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12163607&query_hl=11&itool=pubmed_docsum

Schulke N, Vesanen MS, Sanders RW, Zhu P, Lu M, Anselma DJ, Villa AR, Parren PW, Binley JM, Roux KH, Maddon PJ, Moore JP, Olson WC.
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein.
Journal of Virology. 2002 Aug;76(15):7760-76.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12097589&query_hl=12&itool=pubmed_docsum
Binley JM, Sanders RW, Clas B, Schuelke N, Master A, Guo Y, Kajumo F, Anselma DJ, Maddon PJ, Olson WC, Moore JP.
A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. Journal of Virology. 2000 Jan;74(2):627-43.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10623724&query_hl=13&itool=pubmed_docsum


PRO 140

Jeffrey M. Jacobson, Michael S. Saag, Melanie A. Thompson, Margaret A. Fischl, Ralph Liporace, Richard C. Reichman, Robert R. Redfield, Carl J. Fichtenbaum, Barry S. Zingman, Mahesh C. Patel, Jose D. Murga, Suzanne M. Pemrick, Paul D'Ambrosio, Marti Michael, Hans Kroger, Hieu Ly, Yakov Rotshteyn, Robert Buice, Stephen A. Morris, Joseph J. Stavola, Paul J. Maddon, Alton B. Kremer and William C. Olson
Antiviral Activity of Single-Dose PRO 140, a CCR5 Monoclonal Antibody, in HIV-infected Adults
http://delivery.sheridan.com/index.php?ID=UCP_142660_EP

Shearer WT, DeVille JG, Samson PM, Moye JH Jr, Fletcher CV, Church JA, Spiegel HM, Palumbo P, Fenton T, Smith ME, Graham B, Kraimer JM, Olson WC.
Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140).
J Allergy Clin Immunol. 2006 Aug;118(2):518-21. Epub 2006 May 19. No abstract available.
PMID: 16890780 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/pubmed/16890780?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Murga JD, Franti M, Pevear DC, Maddon PJ, Olson WC.
Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy. 2006 Oct;50(10):3289-96.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17005807&query_hl=2&itool=pubmed_docsum
Ketas TJ, Frank I, Klasse PJ, Sullivan BM, Gardner JP, Spenlehauer C, Nesin M, Olson WC, Moore JP, Pope M.
Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.
Journal of Virology. 2003 Feb;77(4):2762-67.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12552019&query_hl=20&itool=pubmed_DocSum

Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ, Olson WC.
Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
Journal of Virology. 2001 Jan;75(2):579-88.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11134270&query_hl=65&itool=pubmed_docsum
Olson WC, Rabut GE, Nagashima KA, Tran DN, Anselma DJ, Monard SP, Segal JP, Thompson DA, Kajumo F, Guo Y, Moore JP, Maddon PJ, Dragic T.
Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.
Journal of Virology. 1999 May;73(5):4145-55.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10196311&query_hl=63&itool=pubmed_DocSum


METHYLNALTREXONE

Edward Michna, E. Richard Blonsky, Seth Schulman, Evan Tzanis, Amy Manley, Haiying Zhang, Shrividya Iyer, Bruce Randazzo
Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Patients With Chronic, Nonmalignant Pain: A Randomized Controlled Study
The Journal of Pain
http://www.cenveomobile.com/issue/32057

Jay Thomas, M.D., Ph.D., Sloan Karver, M.D., Gail Austin Cooney, M.D., Bruce H. Chamberlain, M.D., Charles Kevin Watt, D.O., Neal E. Slatkin, M.D., Nancy Stambler, M.S., Alton B. Kremer, M.D., Ph.D., and Robert J. Israel, M.D.
Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects.Methylnaltrexone for Opioid-Induced Constipation in Advanced Illness
The New England Journal of Medicine
http://articleworks.cadmus.com/doc/866055
Charles Berde, M.D., Ph.D., and Samuel Nurko, M.D., M.P.H.
Opioid Side Effects – Mechanism-Based Therapy
New England Journal of Medicine
https://articleworks.cadmus.com/doc/dSoftcopy?o=701440&i=866530&c=1760334&atDownload=true

Yuan CS.
Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects.
The Journal of Supportive Oncology. 2004 Mar-Apr;2(2):111-7; discussion 119-22. Review.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15328815&query_hl=70&itool=pubmed_DocSum
Yuan CS, Wei G, Foss JF, O'Connor M, Karrison T, Osinski J.
Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial.
The Journal of Pharmacology and Experimental Therapeutics. 2002 Jan;300(1):118-23.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11752106&query_hl=72&itool=pubmed_docsum

Foss JF.
A review of the potential role of methylnaltrexone in opioid bowel dysfunction.
American Journal of Surgery. 2001 Nov;182(5A Suppl):19S-26S. Review.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11755893&query_hl=68&itool=pubmed_docsum
Yuan CS, Foss JF. Methylnaltrexone: Investigation of Clinical Applications Drug Development Research. 2000; 50:133-141.
[NO PUB MED LINK]

Yuan CS, Foss JF.
Oral methylnaltrexone for opioid-induced constipation.
JAMA : The Journal of the American Medical Association. 2000 Sep 20;284(11):1383-4.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10989399&query_hl=32&itool=pubmed_DocSum
Yuan CS, Foss JF, O'Connor M, Osinski J, Karrison T, Moss J, Roizen MF.
Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial.
JAMA : The Journal of the American Medical Association. 2000 Jan 19;283(3):367-72.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10647800&query_hl=32&itool=pubmed_DocSum

Yuan CS, Foss JF, O'Connor M, Toledano A, Roizen MF, Moss J.
Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial.
Clinical Pharmacology and Therapeutics. 1996 Apr;59(4):469-75.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8612393&query_hl=77&itool=pubmed_docsum

HCV

Cormier EG, Durso RJ, Tsamis F, Boussemart L, Manix C, Olson WC, Gardner JP, Dragic T. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus.
Proceedings of the National Academy of Sciences of the United States of America. 2004 Sept 28;101(39):14067-72.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15371595&query_hl=22&itool=pubmed_DocSum

Cormier EG, Tsamis F, Kajumo F, Durso RJ, Gardner JP, Dragic T. CD81 is an entry coreceptor for hepatitis C virus.
Proceedings of the National Academy of Sciences of the United States of America. 2004 May 11;101(19):7270-74.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15123813&query_hl=24&itool=pubmed_DocSum
Dumonceaux J, Cormier EG, Kajumo F, Donovan GP, Roy-Chowdhury J, Fox IJ, Gardner JP, Dragic T.
Expression of unmodified hepatitis C virus envelope glycoprotein-coding sequences leads to cryptic intron excision and cell surface expression of E1/E2 heterodimers comprising full-length and partially deleted E1.
Journal of Virology. 2003 Dec;77(24):13418-24.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14645599&query_hl=26&itool=pubmed_DocSum

Gardner JP, Durso RJ, Arrigale RR, Donovan GP, Maddon PJ, Dragic T, Olson WC.
L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus.
Proceedings of the National Academy of Sciences of the United States of America. 2003 Apr 15;100(8):4498-503.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12676990&query_hl=42&itool=pubmed_docsum

PSMA

Durso RJ, Andjelic S, Gardner JP, Margitich DJ, Donovan GP, Arrigale RR, Wang X, Maughan MF, Talarico TL, Olmsted RA, Heston WD, Maddon PJ, Olson WC.
A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses.
Clin Cancer Res. 2007 Jul 1;13(13):3999-4008.
PMID: 17606734 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/pubmed/17606734?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Olson WC, Heston WD, Rajasekaran AK.
Clinical trials of cancer therapies targeting prostate-specific membrane antigen.
Rev Recent Clin Trials. 2007 Sep;2(3):182-90. Review.
PMID: 18474004 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/pubmed/18474004?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF, Maddon PJ, Olson WC.
Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
Clinical Cancer Research. 2006 Apr 15;12(8):2591-6.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16638870&query_hl=44&itool=pubmed_DocSum

Schulke N, Varlamova OA, Donovan GP, Ma D, Gardner JP, Morrissey DM, Arrigale RR, Zhan C, Chodera AJ, Surowitz KG, Maddon PJ, Heston WD, Olson WC.
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy.
Proceedings of the National Academy of Sciences of the United States of America. 2003 Oct 28;100(22):12590-5.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14583590&query_hl=82&itool=pubmed_docsum
^ Top of page